Metformin's potential as an anti-ageing therapy faces cautious but exciting prospects

A new review highlights metformin’s promising biological effects on cellular pathways linked to aging, but stops short of recommending it as an anti-ageing pill pending further large-scale trials. Researchers stress its potential to transform healthy lifespan extension if validated in future studies.

A new review in the journal Aging argues that metformin, the long-established type 2 diabetes medicine, has become one of the most serious drug candidates in the search for healthier ageing, but stops well short of recommending it for people who simply want to live longer. The paper, published on 10 August 2026 by Jarra Manneh, May Alasmar and Nady El Hajj of Hamad Bin Khalifa University in Qatar, pulls together findings from cell studies, animal work and human research, and says the case now needs properly powered randomised trials in adults without diabetes.

That matters because the question is no longer just whether metformin lowers blood sugar. Researchers working in geroscience are trying to find treatments that act on the shared biology behind many age-related illnesses at once, rather than tackling heart disease, dementia, cancer and frailty as wholly separate problems. The review notes the World Health Organization’s projection that the number of people aged 60 and over worldwide will rise from 1 billion in 2020 to 2.1 billion by 2050. Metformin is attractive in that context because it is cheap, widely prescribed, and familiar to doctors; ScienceAlert also noted that it is on the WHO’s Essential Medicines list. The PubMed record for the paper identifies it as a review of ageing and longevity evidence across cellular, molecular and organismal research.

The scientific interest rests on what metformin seems to be doing inside cells. The authors write that, “Apart from its primary role in lowering blood glucose levels, metformin has been shown to have several effects at the molecular level.” In practice, that means the drug appears to push cells into sensing an energy shortage, a state that resembles fasting. This switches on AMPK, a cellular energy sensor, which in turn can dampen mTOR, a pathway linked to growth and ageing, while also boosting autophagy, the cell’s waste-disposal and recycling system. The review and later coverage also point to lower oxidative stress, better insulin sensitivity and possible epigenetic effects, including changes involving the enzyme TET2, which helps regulate DNA methylation patterns associated with ageing.

Another strand of the story is in the gut. According to the review, metformin accumulates in the intestine at concentrations far higher than those seen in the blood, making the microbiome a plausible part of its wider effects. The authors say it may encourage short-chain fatty-acid-producing bacteria and raise levels of Akkermansia muciniphila, a microbe linked to the integrity of the gut’s mucus layer. Those changes, they suggest, could help limit inflammation and support metabolic health. Coverage by Aging & Longevity also highlighted the same microbiome route as part of the reason metformin remains of interest well beyond diabetes care.

The most eye-catching results remain in animals. The review says some experiments in C. elegans worms found lifespan gains of roughly 36% to 40%. Mouse results were smaller and less consistent, ranging from about 5.8% to 20.1% in different models, with some studies also reporting delayed tumours. The primate data have drawn particular attention: in a 40-month study of male cynomolgus monkeys, metformin treatment was linked to lower biological age markers across several tissues. The review says the brain appeared almost six biological years younger, which Medical Xpress described as roughly equivalent to 18 human years.

Human evidence is more intriguing than definitive. One small 2022 study of 32 people with type 2 diabetes associated metformin use with 2.7 to 3.4 years less biological ageing on epigenetic clocks. Earlier observational work suggested people with diabetes taking metformin lived up to 15% longer than matched controls not on the drug, and 38% longer than those on sulphonylurea monotherapy. But the review is notably cautious about these findings. It says some of the best-known survival claims have been criticised after failed replication attempts, and that many studies mix together very different outcomes, from mortality to frailty scores to molecular markers, making clean conclusions difficult.

The trial picture is therefore crucial. The proposed Targeting Aging with Metformin, or TAME, study is designed to enrol 3,000 adults aged 65 to 79 and follow them for four years, testing whether one drug can delay several age-related conditions at once, including cardiovascular events, cancer, cognitive decline and death. The review says no results have been published so far and notes comments from Nir Barzilai in 2025 that ARPA-H is now involved in handling the effort. India Today reported that US regulators had agreed the study design, while stressing that metformin has not been approved as an anti-ageing treatment and that repeated funding delays have dogged the project. The same review points to one of the few substantial randomised datasets already available: the MeMeMe trial in more than 1,400 people aged 50 to 79 with metabolic syndrome. There, 1,700mg a day of metformin reduced new type 2 diabetes, but did not prevent cancer, cardiovascular disease or death.

That mixed picture explains why clinicians are urging restraint. India Today quoted Dr Niraj Kumar, an internal medicine specialist, saying: “Beyond its role in diabetes, metformin has also gained attention due to the finding that patients taking it for type 2 diabetes do not only achieve blood glucose improvements but also exhibit health benefits that surpass the intended use.” Even so, he said the evidence still needs confirmation in large trials of healthy individuals. The review also underlines that a familiar drug is not a risk-free one: it cites gastrointestinal side effects in around 30% of patients in one study, long-term links to vitamin B12 deficiency, and the rare but serious risk of metformin-associated lactic acidosis, particularly in older people with impaired kidney function.

For now, the strongest case for metformin is not that it is a proven longevity pill, but that it offers a rare, well-characterised tool for probing how ageing biology might be altered. If future trials show that one cheap generic drug can delay several major diseases at once, that would change more than diabetes care. Until then, the review’s real message is a cautious one: metformin may help explain healthy ageing, but it has not yet earned a place as a medicine for it.